References
- Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American heart association. AHASC. Stroke Statistics Subcommittee. Circulation. 2016;133(4):e38–60.
- Potential new drugs for the treatment of heart failure.
- O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Eng J Med. 2011;365:32–43.
- Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. J Am Coll Card Heart Failure. 2012;1:103–111.
- McGuane JT, Debrah JE, Sautina L, et al. Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology. 2011;152(7):2686–2696.
- Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomized, placebo-controlled trial. Lancet. 2013;381(9860):29–39.
- Mitrovic V, Luss H, Nitsche K, et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J. 2005;150:1239.el-8.
- Mitrovic V, Seferovic PM, Simeunovic D, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J. 2006;27:2823–2832.
- McMurray JJV, Packer M, Desai A, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
- Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT: a randomized placebo-controlled study.). Lancet. 2010;376:875–885.
- Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011;378:676–683.
- Greenberg BH, Chou W, Saikali KG, et al. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. J Am Coll Cardiol HF. 2015;3:22–29.
- Gheorghiade M, Greene SJ, Bulter J, et al. Effect of vericaguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction. Jama. 2015;1:13.
- Pitt B, Anker SD, Böhm M, et al. Rationale and design of miner alocorticoid receptor antagonist tolerability study-heart failure (ARTS-HF): a randomized study of finerenone vs eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015;17:224–232.
- Gao R, Zhang J, Cheng L, et al. A phase ii, randomized double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombianant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cordiol. 2010;55:1907–1914.
- Abbour A, Hayward CS, Keogh, et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favorable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011;13:83–92.
- Ghali JK. The COHERE registry: hype or hope? J Card Fail. 2000;6(3):272–275.
- Ghali JK. A clinician’s perspective on clinical trials. J Card Fail. 2001;7(1):1–3.
- Miro O, Gil V, Muller C, et al. How does a clinical trial fit into the real world? The RELAX-AHF study population into the EAHFE registry. Clin Res Cardiol. 2015;104:850–860.